Super Micro Stock Jumps 19% as AI Server Demand Drives Strong 2027 Outlook 
Lenovo Revenue Surges 43% as AI Demand Drives Record First-Quarter Growth 
Google Pushes Gemini AI Overhaul as Sergey Brin Targets Model Supremacy 
Micron Stock Upgraded to Buy as New Street Sees $2 Trillion Valuation Potential 
Alphabet Shifts AI Strategy Toward Commercial Growth, Goldman Sachs Says 
SMIC Shares Rally as Q2 Profit Surges 262% on Strong Chip Demand 
Apple Develops China-Specific AI Model With Alibaba as Apple Intelligence Launch Nears 
Ford to Move Some Lincoln Production From China to U.S. in 2030 
LG, Nvidia Expand AI Partnership With Humanoid Robots, AI Factories 
Australia’s Corporate Leaders Face Parliament Over KPMG Client Data Scandal 
Bill Ackman’s Pershing Square Returns to Netflix With Major New Stake 
Antofagasta Shares Drop 5% as Miner Cuts 2026 Copper Production Forecast 
Paramount Skydance Clears Regulatory Hurdles for Warner Bros. Discovery Deal 
Stripe, Advent Reportedly Pursue $53 Billion PayPal Takeover 
Pandora Shares Rise as Q2 Results Beat Forecasts, 2026 Outlook Raised 
Bernstein Picks BYD and Xiaomi as Top China EV Stocks Despite Weaker Demand 
Anthropic Eyes $6B Decart AI Acquisition Ahead of Mega IPO 
Add as a preferred source on Google
PARSIPPANY, N.J., May 10, 2017 -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that members of its management team are scheduled to present at the Bank of America Merrill Lynch 2017 Healthcare Conference at 8:00 AM PT on Wednesday, May 17, 2017 in Las Vegas.
A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors & Media” section of the company’s website at investor.pacira.com. A replay of the webcast will be archived on the Pacira website for two weeks following the presentation date.
About Pacira
Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is a specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. The company’s flagship product, EXPAREL® (bupivacaine liposome injectable suspension), indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia, was commercially launched in the United States in April 2012. EXPAREL and two other products have successfully utilized DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. Additional information about Pacira is available at www.pacira.com.
Company Contact: Pacira Pharmaceuticals, Inc. Susan Mesco (973) 451-4030 [email protected]
